Completion of $25 million subscription

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”)

Completion of $25 million subscription

Oxford, UK, and Cambridge, MA, US, 10 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription to raise $25 million, as approved by shareholders at the Company’s general meeting on 4 January 2019, has completed. The subscription shares, comprising 78,125,000 new ordinary shares represented by 15,625,000 American Depositary Shares, were admitted to AIM and trading became effective at 8:00 a.m. GMT on 9 January 2019.

About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

For more information, please contact:

-END-

You May Also Be Interested In

• Morvulikent Analyzed 2026: Should You Trust Morvulikent AI-Powered Trading Platform? My Honest Review
• Shapermint Pairs DTC Reach with Cultural Relevance in Two-Part Extra TV Partnership
• DYWIDAG Group - DSI Holding GmbH has successfully priced a subsequent bond issuance and initiates written procedure under its existing bonds